Zura Bio Limited to Engage with Investors at Key Healthcare Conferences in March 2026
Zura Bio Limited , a clinical-stage biotechnology company dedicated to discovering and developing innovative therapies for patients suffering from serious and debilitating autoimmune and inflammatory diseases, today announced its participation in two prominent investor conferences scheduled for March 2026. These engagements underscore Zura Bio’s ongoing commitment to investor transparency and its mission to bring novel medicines to patients with unmet medical needs.
Zura Bio has built a reputation as a leader in the biotechnology space, focusing on therapies that are not only novel but also differentiated in their mechanisms of action. The Company’s pipeline emphasizes the development of treatments designed to deliver meaningful clinical benefit for patients whose conditions are often chronic, progressive, and life-altering. By addressing complex autoimmune and inflammatory diseases, Zura Bio aims to provide physicians and patients with therapeutic options that go beyond symptomatic relief to potentially transformative outcomes.
Upcoming Investor Conferences
As part of its strategic investor outreach, Zura Bio’s management team will participate in two high-profile investor events taking place in Miami, Florida. These events provide a platform for the Company to update investors on recent progress across its pipeline, outline strategic objectives, and engage directly with the investment community.
1. Leerink Global Healthcare Conference
The first event is the Leerink Global Healthcare Conference, a prestigious forum that brings together executives, investors, and thought leaders from across the healthcare industry. The conference, widely recognized for its focus on innovative biopharmaceutical companies, provides an ideal stage for Zura Bio to communicate its clinical and corporate developments to an engaged and influential audience of institutional investors and analysts.
Zura Bio’s management will participate in a fireside chat scheduled for Tuesday, March 10, 2026, at 2:20 p.m. ET. This session will feature a detailed discussion of the Company’s scientific strategy, ongoing clinical trials, and long-term vision for its therapeutic pipeline. In addition to the scheduled fireside chat, members of Zura Bio’s management will also hold one-on-one investor meetings to provide more personalized briefings, answer questions, and discuss the Company’s approach to innovation in autoimmune and inflammatory disease treatment.
For investors and stakeholders unable to attend in person, Zura Bio will provide a live webcast of the fireside chat. The webcast will be accessible through the Investors section of the Company’s website under News & Events, ensuring broad access to the insights shared during the session. Furthermore, a replay of the webcast will remain available for at least 30 days following the event, allowing stakeholders to review the presentation at their convenience and ensuring transparency in the Company’s communications.
2. Jefferies Biotech on the Beach Summit
The second conference in which Zura Bio will participate is the Jefferies Biotech on the Beach Summit, taking place on Wednesday, March 11, 2026, also in Miami, Florida. This summit is renowned for convening leading biotech executives and investors to discuss emerging trends, pipeline progress, and investment opportunities in the life sciences sector.
At the Jefferies Biotech on the Beach Summit, Zura Bio’s management team will focus primarily on investor meetings, engaging with a diverse group of institutional and individual investors. These discussions will highlight the Company’s ongoing clinical programs, key milestones achieved, and strategic plans for advancing its innovative therapies through late-stage development and regulatory pathways. Such direct engagement provides investors with an opportunity to ask in-depth questions about the Company’s pipeline, scientific approach, and market positioning, offering critical insight into Zura Bio’s growth potential.
Zura Bio’s Pipeline and Strategic Vision
Zura Bio’s participation in these conferences comes at a time of significant momentum for the Company. The biotechnology sector continues to experience rapid scientific and clinical advancements, and Zura Bio is well-positioned to leverage its deep expertise in immunology and inflammation to develop therapies that could meaningfully alter disease progression.
The Company’s pipeline includes multiple clinical-stage programs targeting autoimmune and inflammatory conditions that represent high unmet medical need. Zura Bio is focused on advancing therapies that offer differentiated mechanisms of action, with the goal of improving both patient outcomes and quality of life. This commitment reflects the Company’s broader mission: to transform the treatment landscape for complex diseases through science-driven innovation.
By engaging with investors at leading healthcare conferences, Zura Bio not only shares updates on its clinical progress but also communicates the strategic rationale underpinning its approach to drug development. These interactions provide valuable opportunities for feedback from the investment community and facilitate a deeper understanding of the Company’s potential for long-term value creation.
Investor Access and Transparency
Transparency and open communication with stakeholders are core principles at Zura Bio. By providing live webcasts of its conference presentations and making replays accessible, the Company ensures that all investors, regardless of location, have the opportunity to stay informed about its strategic direction and operational developments. These initiatives are part of Zura Bio’s broader investor relations program, which emphasizes timely, accurate, and comprehensive communication to foster trust and engagement with the investment community.
About Zura Bio Limited
Zura Bio Limited (Nasdaq: ZURA) is a clinical-stage biotechnology company focused on the discovery and development of innovative medicines to treat patients with serious and debilitating autoimmune and inflammatory diseases. The Company’s mission is to deliver therapies that meaningfully improve patient outcomes and quality of life by targeting conditions with significant unmet medical need. Through its commitment to scientific excellence, strategic partnerships, and patient-centered development, Zura Bio aims to transform the treatment paradigm for complex diseases and drive long-term value for both patients and investors.
